JSPR (Jasper Therapeutics) ROCE %: -252.01% (As of Mar. 2026)


JSPR Jasper Therapeutics Inc JSPR
29 GF Score
Price $0.45
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics ROCE %?

Jasper Therapeutics JSPR +6.44% 29 ROCE % is -252.01% as of Mar. 2026. GuruFocus rates JSPR with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jasper Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -252.01%.

Jasper Therapeutics  (NAS:JSPR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jasper Therapeutics ROCE % Related Terms

Jasper Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Jasper Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jasper Therapeutics ROCE % Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -70.17 -80.67 -111.23 -103.60 -192.30

Jasper Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -158.67 -304.10 -245.74 -214.74 -252.01
JSPR
29GF Score
Jasper Therapeutics Inc JSPR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jasper Therapeutics ROCE % Calculation

Jasper Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-83.883/( ( (79.899 - 15.237) + (35.779 - 13.2) )/ 2 )
=-83.883/( (64.662+22.579)/ 2 )
=-83.883/43.6205
=-192.30 %

Jasper Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-43.808/( ( (35.779 - 13.2) + (21.184 - 8.996) )/ 2 )
=-43.808/( ( 22.579 + 12.188 )/ 2 )
=-43.808/17.3835
=-252.01 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -252.01% mean?
Jasper Therapeutics (JSPR) has a ROCE % of -252.01% as of Mar. 2026.
Is Jasper Therapeutics' ROCE % too high?
Jasper Therapeutics' current ROCE % is -252.01%. Overall, Jasper Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' ROCE % compare to CVKD and BRTX?
Jasper Therapeutics' ROCE % of -252.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Jasper Therapeutics's current ROCE % is -252.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current ROCE % of -252.01%. The current ROCE % is -252.01%. Jasper Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current ROCE % is -252.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
29GF Score

Get the complete analysis for JSPR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price